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Background: Stroke is one of the leading causes of neuronal death. Sesamin is known for neuroprotection by its
antioxidant and anti-inflammatory properties but it lacks blood–brain barrier (BBB) activity. A panel of sesamin
derivatives was screened and 3-bis (3-methoxybenzyl) butane-1,4-diol (BBD) was selected for high BBB activity and
tested for its neuroprotective effect.
Methods: The focal cerebral ischemia of Sprague–Dawley rats and hypoxia models of murine BV-2 microglia or
PC12 cells under oxygen/glucose deprivation were used for in vivo and in vitro test, respectively. Lipid peroxidation
and superoxide dismutase (SOD) activity from the ischemic brain were tested and reactive oxygen species (ROS),
cytokine production, prostaglandin (PGE2) and related signaling pathways from hypoxic cells were examined by
ELISA or Western blot assay, respectively.
Results: BBD showed a protective effect when given 90 min after the focal cerebral ischemia. It also reduced
lipid peroxidation and preserved SOD activity from the ischemic brain. The mechanism of BBD was further
confirmed by attenuating ROS, cytokine production, and PGE2 release from hypoxic BV-2 or PC12 cells. BBD
significantly reduced hypoxia-induced c-Jun N-terminal kinases (JNK) and modulated AKT-1 and caspase-3
(survival and apoptotic pathways) in BV-2 cells, and inhibited hypoxia-induced JNK and cyclooxygenase-2
activation in PC12 cells.
Conclusions: The neuroprotective effect of BBD on ischemia/hypoxia models was involved with antioxidant and
anti-inflammatory effects. The result would help the development of new CNS drug for protection of ischemia/
hypoxia injury.
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Stroke is the most common disease in the elderly popu-
lation. Ischemic stroke is commonly caused by throm-
bosis that results in acute cerebrovascular disease and
the lack of glucose and oxygen would damage the neur-
onal cells. In Taiwan, cerebrovascular disease is one of
the leading causes of death in recent years (Department
of Health, Taiwan). Brain ischemia/hypoxia is character-
ized by an increase reactive oxygen species (ROS) gener-
ation and cytokine-mediated inflammatory reactions [1].* Correspondence: kcjeng@gmail.com
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unless otherwise stated.Studies have shown that ischemia/reperfusion of brain
can cause cell damage by increasing inflammation from
oxidative stress [2,3]. Previously we reported that sesamin
protected cerebral ischemia and neuronal cell injuries
under stress [4,5]. However, sesamin might not penetrate
the BBB easily because it has to be pretreated for its neu-
roprotective effect to ischemia/hypoxia-induced injuries
[4-6]. A good neuroprotective agent should be able to pass
the blood–brain barrier (BBB) to reach the brain target
site [7,8].
Ischemia/hypoxia-induced ROS and cytokine can be
scavenged by antioxidants [9]. Rat pheochromacytoma
(PC12) cells and murine microglia BV-2 cells have been
used as neuronal stress models [4,5,10]. Specifically,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hou et al. Journal of Biomedical Science 2014, 21:15 Page 2 of 10
http://www.jbiomedsci.com/content/21/1/15extracellular signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK) and p38 mitogen-activated protein
kinase (MAPK) signaling pathways can be activated by
ROS in PC12 cell and BV-2 cells [4,5]. Hypoxia-ischemia
induces apoptosis in the brain is evident by release of cyto-
chrome c and activation of caspase-3 [11]. Therefore in the
present study, a compound, 3-bis (3-methoxybenzyl)
butane-1,4-diol (BBD, Figure 1), with high membrane per-
meability was selected from a panel of newly synthesized
sesamin derivatives to test its neuroprotective effect.
The possible mechanism of BBD was investigated with
ischemic brain and hypoxia models under oxygen and
glucose deprivation (hypoxia) for ROS, cytokine, and
PGE2 production. Hypoxia-induced MAPKs, apoptotic
pathways, and COX-2 were also studied.
Methods
Reagents
Dimethylsulfoxide (DMSO), lucifer yellow, n-Dodecane,
phosphate buffered saline (PBS), theophylline, and verap-
amil were obtained from Sigma-Aldrich Chemical (St.
Louis, MO, USA). Porcine polar brain lipid (PBL) was pur-
chased from Avanti Polar Lipids Inc. (Alabaster, AL,
USA). 2′,7′-Dichlorodihydrofluorescein diacetate (H2DCF-
DA) was obtained from Molecular Probe (Eugene, Oregon,
USA). Fetal bovine serum (FBS) was obtained from Gibco
Invitrogen (Grand Island, NY, USA). Dulbecco’s Modified
Eagle’s medium (DMEM) were purchased from GIBCO
(Grand Island, NY, USA). Anti-phospho-p38, ERK, JNK,
and β-actin antibodies were purchased from Abcam (Cam-
bridge, UK). Anti-Akt1 (pSer473) antibody was purchased
from Calbiochem (Darmstadt, Germany). 3-bis (3-methox-
ybenzyl) butane-1,4-diol (BBD) was kindly provided from
Joben Bio-Medical Co. (Kaohsiung, Taiwan).
Membrane permeability assay
The blood–brain barrier limits drug access into the
brain, due to tight junctions, membrane drug transporters,Figure 1 The chemical structure of sesamin and BBD.and unique lipid composition. Porcine whole-brain lipid is
successfully used in passive permeability test for CNS
drugs [7,8].
The parallel artificial membrane permeation assay
(PAMPA) was carried out in a sandwich-like 96-well
PAMPA plate formed by a top filter plate containing
acceptor wells and a bottom plate containing donor
wells. Each composite well was divided into two cham-
bers: 300 μl of donor solution (test article or QC stan-
dards) at the bottom and 200 μl of acceptor buffer (PBS
buffer containing 5% DMSO) at the top, separated by
a polyvinylidene fluoride (PVDF, 0.45 μm pore size)
membrane, coated with 4 μl of 20 mg/ml porcine polar
brain lipid (PBL) in n-dodecane. Stock solutions of
2 mg/mL of a sesamin derivative (BBD), theophylline
(low permeability standard), verapamil (high perme-
ability standard), and lucifer yellow (used to assess lipid
layer integrity in donor well) were prepared in DMSO and
then diluted 20-fold in PBS buffer at pH 7.4 to yield final
concentrations of 100 μg/ml of each of working stock
solutions. The final DMSO concentration in working
stock solution is 5%. Each compound was performed
in triplicate. The test compound diffused from the donor
well through the lipid membrane and into the acceptor
well. The sandwich plate was placed with the plate
lid and incubated at room temperature for approxi-
mately 18 h. After reaching diffusion equilibration,
the PAMPA sandwich plate was disassembled and the
concentration of drug in the acceptor, the donor, and
the reference wells was determined using a TECAN
microplate reader (Durham, NC, USA). Effective per-
meability (Pe) of the compounds was calculated using
the Microsoft Office Excel 2010. The range for Pe of
a BBB + compound (high BBB permeation predicted):
Pe (10
-6 cm s-1) > 4.0; BBB- compound (low BBB perme-
ation predicted): Pe (10
-6 cm s-1) < 2.0; and BBB+/- com-
pound (BBB permeation uncertain): Pe (10
-6 cm s-1) from
4.0 to 2.0 [7].BBD
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Twenty-four male Sprague–Dawley (SD) rats (200~250
gm) were purchased from National Animal Center, Taipei,
Taiwan and randomly divided into the control (normal
saline), and BBD groups. The experiment was approved by
Institutional Animal Care and Use Committee, Taichung
Veterans General Hospital (IACUC LA-97490). Rats
were injected intraperitoneally (i.p.) with BBD (10 mg/kg)
90 min after MACO experiment. Each SD rat was anes-
thetized with chlorohydrate (400 mg/kg) i.p. and its body
temperature was maintained at 37°C with a heating pad
(CMA/150). A midline neck incision was made and the
right carotid artery was exposed and separated from the
vago-sympathetic trunk. The right carotid artery was
loosely encircled with a 4-O suture for later occlusion.
The SD rat’s head was placed in a stereotaxic frame (David
Kopf, CA, USA) with the nose bar positioned 4.0 mm
below the horizontal line. Following a midline incision,
the skull was partially removed to expose the right
middle cerebral artery. The middle cerebral artery was
loosely encircled with an 8-O suture for later occlu-
sion. A focal cerebral ischemia was induced by occlu-
sion of the right common carotid artery and the right
cerebral artery (MCAO) for 60 min, followed by reper-
fusion. A laser probe (0.8 mm in diameter) of a Laser
Doppler Blood Flow monitor (MBF 3D, Moor Instruments,
Axminster, UK) was positioned onto the cortex with its
tip close to the middle cerebral artery. Cerebral blood
flow dropped to less than 5% of basal after the occlusion
of the MCAO. Cerebral blood flow reached its minimal
levels within 5 min after the start of the occlusion and was
confirmed to remain at this level throughout the moni-
toring period to ensure the validity of the stroke model.
Twenty-four hours after cerebral ischemia, each SD rat
was anesthetized and perfused transcardially with isotonic
heparinized saline and 2,3,5-triphenyltetrazolium chloride
(TTC). The brain was then removed and sliced into five
2-mm-thick coronal sections for TTC staining.
Cell culture
Murine BV-2 microglial cell line was maintained in DMEM
supplemented with 10% (v/v) FBS, 100 U/ml penicillin and
100 μg/ml streptomycin (P/S) in a humidified incubator
under 5% CO2 at 37°C. Rat pheochromacytoma PC12 cell
line was maintained in DMEM supplemented with 10%
FBS, 5% horse serum, P/S at 37°C under 5% CO2. Conflu-
ent cultures were passaged by trypsinization. In all experi-
ments, the cells were treated with BBD immediately before
hypoxia. BBD was dissolved in DMSO. The final concentra-
tion of DMSO added to cells never exceeded 0.1% (v/v).
Hypoxia
On the day of experiment, culture media were replaced
with glucose-free DMEM, then, gassed with 85% N2,10% H2, and 5% CO2 for various time periods in the ab-
sence or presence of various doses of BBD.
MTT assay
Cell viability was measured using blue formazan that was
metabolized from colorless 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) by mitochon-
drial dehydrogenases, which are active only in live cells.
PC12 or BV2 cells were preincubated in 24-well plates at a
density of 5 × 105 cells per well for 24 h. Cells incubated
with various concentrations of BBD were under hypoxia
for 30 min, and incubated in 0.5 mg/ml MTT at 37°C.
One hour later, 200 μl of solubilization solution were
added to each well and absorption values read at 540 nm
on microtiter plate reader (spectraMAX 340, Molecular
Devices, Sunnyvale, CA, USA). Data were expressed as the
mean percent of viable cells vs. control.
LDH assay
Cytotoxicity was determined by measuring the release of
LDH. PC12 or BV-2 cells treated with various concen-
trations of BBD were stressed with hypoxia for one hour
and the supernatant was then assayed for LDH activity.
An absorbance was read at 490/630 nm using a spectra-
MAX 340 microtiter plate reader. Data were expressed
as the mean percent of viable cells vs. the control.
Generation of reactive oxygen species
Intracellular accumulation of ROS was determined using
H2DCF-DA, which is a nonfluorescent compound that
accumulates in cells following deacetylation. H2DCF
then reacts with ROS to form fluorescent dichlorofluores-
cein (DCF). PC12 cells were plated in 96-well plates and
grown for 24 h before addition of DMEM plus 10 μM
H2DCF-DA, incubated for 60 min at 37°C, and treated
with various concentrations of BBD for hypoxia 30 min.
Cells were then washed twice at room temperature with
Hank’s balanced salt solution (HBSS without phenol red).
Cellular fluorescence was monitored on a Fluoroskan
Ascent fluorometer (Labsystems Oy, Helsinki, Finland)
using an excitation wavelength of 485 nm and emission
wavelength of 538 nm.
Measurement of cytokine assay
Cytokines (IL-1β, IL-6) and PGE2 were measured using
ELISA kits (R&D, Minneapolis, MN, USA). The absorbance
at 450 nm was determined using a microplate reader (spec-
traMAX 340).
Western blot
Samples containing 25 μg of protein were separated on
12.5% (w/v) sodium dodecyl sulfate-polyacrylamide gels,
and transferred to immobilon polyvinylidenedifluoride
membranes (Millipore, Bedford, USA). The membranes
Table 1 The PAMPA-BBB permeation of BBD
Compound Pe (10-6 cm/s) Known Pe (10-6 cm/s) Classification
Theophylline 0.08 ± 0.01 0.12 ~ 0.18 BBB-
Verapamil 23.82 ± 1.82 16 ~ 23 BBB+
Testosterone 34.08 ± 4.78 17 BBB+
BBD 20.87 ± 3.05 - BBB+
Sesamin 0.00 ± 0.01 - BBB-
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TBST buffer to block non-specific binding, then ERK, p38
JNK, AKT-1, COX-2, caspase-3, β-actin proteins for neuron
cells were detected by a chemiluminescence detection sys-
tem according to the manufacturer’s instructions (ECL,
Amersham, Berkshire, UK).
Superoxide dismutase (SOD) assay
Superoxide dismutase (SOD) activity was determined by a
Superoxide Dismutase assay kit (Cayman, Ann Arbor, MI,
USA). This method was based on the formation of red
formazan from the reaction of 2- (4-iodophenyl) -3- (4-ni-




















Figure 2 In vivo effect of BBD on the cerebral ischemia. SD rats treated
(A). Data are expressed as mean ± SEM. *: P < 0.05 as compared to the non
were determined by commercial assay kits (Cayman, Ann Arbor, MI, USA). M
but reduced by BBD (B) and SOD activity was restored by BBD (C). Data ar
control. (n = 4).radical and assayed in a spectrophotometer at 505 nm. The
inhibition of the produced chromogen was proportional to
the activity of the SOD present in the sample. A 50% in-
hibition was defined as one unit of SOD, and the specific
activity was expressed as units per milligram protein.
Lipid peroxidation
Lipid peroxidation is quantified by measuring malondial-
dehyde (MDA) of PC12 cells and brain tissue of SD rats
by lipid peroxidation (LPO) assay kit (Cayman). This kit
works on the principle of condensation of one molecule of
either MDA or 4-hydroxyalkenals with two molecules of
N-methyl-2-phenylindole to yield a stable chromophore.
MDA levels were assayed by measuring the amount
expressed in 5 × 105 cells of PC12 and SD brain tissue, and
the absorbance at 500 nm was determined using a micro-
plate reader (spectraMAX 340).
Statistical analysis
Data were expressed as the mean ± SEM. In animal study,
TTC data were analyzed by analysis of variance (ANOVA)











































with BBD i.p. 90 min after MACO had reduced infarct sizes of brains
-treated ischemic control. (n = 8). SOD activity and lipid peroxidation
alondialdehyde (MDA) of SD rats was increased by ischemic stress





















































































































Figure 3 Effect of BBD on cell viability and cytotoxicity of PC12 and BV-2 cells under hypoxia. The cells were treated with hypoxia alone
or in the presence of various concentrations (1, 10, 20 μM) of BBD for 30 min. Cell viability of PC12 (A) and BV-2 cells (C) was increased and the
LDH release, reduced (B, D) from hypoxia dose-dependently by BBD. Data are expressed as mean ± SEM of three independent experiments in
triplicate. *: P < 0.05 as compared to the hypoxia control.
Hou et al. Journal of Biomedical Science 2014, 21:15 Page 5 of 10
http://www.jbiomedsci.com/content/21/1/15considered to be statistically significant. For In vitro study
with single variable comparisons, Student’s t-test was used.
For multiple variable comparisons, data were analyzed by
one-way ANOVA followed by Scheffe’s test.
Results
In vivo effect of BBD on the cerebral ischemia
BBD had a high membrane permeability by PAMPA
assay and was regard as a BBB permeable agent (Table 1).
SD rats treated i.p. with BBD (10 mg/kg) 90 min after
MCAO-induced ischemia reduced 66% of the infarct size
as compared to the cerebral ischemia group (from 16.1 to
4.9%, P < 0.05; Figure 2A). MDA level of the BBD group
was decreased 6% (from 83 μM to 78 μM) as compared to
the ischemia group (Figure 2B). BBD treatment increased
a 24% SOD activity (from 68 μ/mL to 84 μ/mL) as com-
pared to the ischemia group (Figure 2C).
Protection of hypoxic damage
In order to investigate the protective mechanism of BBD,
an in vitro hypoxia model was studied with neuronal cell-
lines. Hypoxia can induce free radicals and damageneuronal cells, therefore the cell viability and LDH released
from PC12 and BV-2 cells were measured using MTT and
LDH ELISA assays. As shown in Figure 3A, the cell viability
of PC12 cells under hypoxia for 30 min was preserved by
the presence of BBD (1 to 20 μM). Hypoxia-induced LDH
released was also decreased by BBD treatment (P < 0.05,
Figure 3B). Similarly, BV-2 cells were protected by BBD
under hypoxia (P < 0.05, Figure 3C,D).
ROS scavenging effect of BBD
Under hypoxia, ROS (as DCF signal) was increased nearly
half (in PC12 cells) to four-fold (in BV-2 cells) as com-
pared with their control cells. BBD protected cells against
hypoxia-induced cell toxicity by decreasing the ROS accu-
mulation in both cells (Figure 4A,B). The increase in
MDA level was suppressed by BBD in hypoxia-exposed
PC12 or BV-2 cells as compared with the control cells
(Figure 4C,D, P < 0.05).
BBD inhibited IL-1, IL-6 and PGE2
BBD dose-dependently decreased the production of the





































































































































































Figure 4 Effects of BBD on hypoxia-induced ROS generation, IL-1, IL-6 and PGE2 productions. PC12 and BV-2 cells were treated with 1, 10,
20 μM of BBD for 30 min. BBD reduced the generation of ROS under hypoxia in PC12 (A) and BV-2 (B) cells. MDA of PC12 (C) and BV-2 (D)
cells were induced by 30-min hypoxia and reduced by BBD. BV-2 cells were treated with 1, 10, 20 μM of BBD under hypoxia 30 min. BBD
concentration-dependently reduced hypoxia-induced IL-1 (E), IL-6 (F) and PGE2 (G) production from BV-2 cells. Data are expressed as mean
± SEM of 3 independent experiments in triplicate. *: P < 0.05 as compared to the hypoxia control, n = 3.
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Figure 5 (See legend on next page.)
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Figure 5 BBD inhibited hypoxia-induced phospho-JNK MAP kinase, AKT-1, COX-2 and Caspase-3 under hypoxia. The effect of BBD (1, 10,
20 μM) on hypoxia-activated cell signaling pathways was determined by Western blotting under hypoxia stress in BV-2 cells for 10 min (A) and
for 30 min (B). Similarly, BBD effectively reduced the activation of JNK MAP kinase and COX-2 (C, D) in PC12 cells. C: normal control. Data are
expressed as mean ± SEM of three independent experiments. *: P<0.05 as compared to hypoxia control.
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ated the effect of BBD on hypoxia-induced PGE2 pro-
duction. BV-2 cells were incubated with 1, 10, 20 μM of
BBD then subjected to hypoxia for 30 min. The results
showed that BBD (10 and 20 μM) decreased PGE2 re-
lease from BV-2 cells significantly (P < 0.05, Figure 4G).
BBD inhibited hypoxia-induced JNK MAPK, COX-2 and
caspase-3 activation
The effects of BBD (1, 10, 20 μM) on hypoxia-induced
signaling pathways were further examined by Western
blot assay (Figure 5). BBD (20 μM) reduced expression of
the following proteins: JNK (88 ± 6%), ERK (10 ± 7%), p38
(-8 ± 10%) MAPKs, AKT-1 (45 ± 6%), Caspase-3 (50 ± 7%),
and COX-2 (13 ± 7%), respectively to the 10 min hypoxia-
induced BV-2 cells (*P < 0.05; Figure 5A). This result is
better than that of the 30 min hypoxia-induced BV-2 cells
(*P < 0.05; Figure 5B). Similarly, BBD (20 μM) also sup-
pressed hypoxia induced expression of the signaling pro-
teins in PC12 cells: JNK (86 ± 5%), ERK (9 ± 7%), p38 (-10
± 9%) MAPKs, and COX-2 (75 ± 11%), respectively (*P <
0.05; Figure 5C). This was better than that of the 30 min
hypoxia-induced PC12 cells (*P < 0.05; Figure 5D).
Discussion
The present study showed that BBD could pass the BBB
by PAMPA assay and significantly protected animals
from the focal cerebral ischemia. Furthermore, BBD was
able to suppress MDA and preserve SOD activity in the
ischemic rat brain. BBD at the concentrations of 10 to
20 μM, decreased hypoxia- induced cell viability, ROS
generation and MDA levels in BV-2 and PC12 cells.
Excessive ROS production in the brain is believed to
contribute to neurodegenerative processes [12,13]. Various
dietary-derived antioxidants that inhibit the hypoxia-
induced inflammation response may have neuroprotective
potential [14,15]. Since sesamin and its related structure
were reported to have protective effect on the hypoxia-
induced inflammatory and oxidative stress [5,16], BBD, a
sesamin derivative would have a similar effect. Effect of
BBD on hypoxia-induced MDA stress might be through
the activation of antioxidant signaling pathway such as
Nrf2/ARE [17].
We found that 10 to 30 min hypoxia could significantly
induce the activation of JNKs, AKT-1, and caspase-3 ex-
pression in BV-2 cells and JNK, ERK, COX-2 expression
in. PC12 cells. Inhibition of JNK MAPK, COX-2 andcaspase-3 can be expected to be beneficial in injuries
involving microglia activation and inflammation. Specific
inhibitors of JNK MAPK have been proven to reduce in-
flammation, slow down microglia activation and provide
neuroprotective effects [4,18,19]. Studies have shown that
antioxidant compounds inhibit JNK MAPK activation
in microglia represent potential anti-inflammatory effects
and protect neurons damage [5,20,21]. In addition, an-
tioxidant compounds inhibit JNK MAPK activation in
neuron and cardiomyocyte cells represent potential pro-
tective effects from hypoxic damage [5,22-24]. Sesamin
can regulate microglial activities by inhibition of the intra-
cerebral hemorrhage-induced p44/42 MAPK pathway and
protect neuronal cells by inhibition of hypoxia-induced
ERK, JNK, p38 MAPK [5,25]. BBD, a sesamin derivative
also suppressed hypoxia-induced JNK MAPK expression
in both cells significantly. Studies have shown that hypoxia
induces MAPK activation and apoptosis factor Caspase-3
in vitro and in vivo [4,11]. Therefore, we evaluated the
effect of BBD on hypoxia-induced signaling pathways in-
cluding MAP kinases (JNK, ERK, p38), AKT-1, Caspase-3
and COX-2. Western blot analysis revealed that BBD (10
and 20 μM) significantly reduced JNK MAPK, AKT-1 and
Caspase-3 expression in BV-2 cells as compared to hyp-
oxia controls (Figure 5A,B). Similarly, BBD significantly
reduced JNK MAPK and COX-2 expression in PC12 cells
with both 10 and 30 min hypoxia as compared to hypoxia
controls (Figure 5C,D). The results suggested that BBD re-
stored the cell viability under hypoxic stress (Figure 3)
through various pathways in each cells. This also agrees
with a recent study that agent protects neuronal cells from
H2O2-induced cell death, DNA fragmentation, and activa-
tion of caspase-3 and MAP kinase can ameliorate ische-
mic brain injury [26].
Induction of antioxidant enzymes has been considered as
a promising strategy to combat with oxidative stress-related
diseases. Previous studies shown that neuroprotective
effects of antioxidants are due to increasing the level of
antioxidant enzymes (e.g., SOD, catalase, G6PD), lower-
ing of ROS, and preventing calcium release [5]. SOD is
an important enzyme for eliminating free radicals and pro-
tect brain tissues from the ischemic injury [27]. Recently a
study shows that sesamin and metabolites induce phase II
antioxidant enzymes such as heme oxygenase-1 (HO-1)
by activation of Nrf2/ARE (antioxidant response element)
signaling and suggesting their potential to reduce oxi-
dative stress and ameliorate oxidative stress-related
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suppress MDA and preserve SOD activity in the ischemic
rat brain and inhibited 40-50% of hypoxia-induced ROS,
IL-1, and IL-6 production, it might also activate this anti-
oxidant signaling pathway, and awaits future study.
ROS could induce cell damage by activating MAPK, and
the nuclear transcription factor c-Jun [28]. The downstream
of ROS signaling pathway could be associated with micro-
glia activation. Since ROS are cytotoxic mediators in mi-
croglia [28]. BBD may also down-regulate hypoxia-induced
inflammatory factor production via the inhibition of ROS
generation which would reduce the activation of IL-1 and
IL-6 cytokines in BV-2 cells. The abilities of BBD to inhibit
the hypoxia-induced COX-2 protein might be due to de-
creased attenuation of ROS signal, and reduced JNK MAPK
in PC12 cells. Caspase-3 is an important apoptosis factor
for neuronal cells [26]. Application of BBD (100 μM) alone
was not toxic to neurons (data not shown) and BBD at the
lower concentration (20 μM) inhibited the inflammation
response in BV-2 and PC12 cells under hypoxia. BBD
significantly reduced infarct volume (about 66%) of is-
chemic brain in SD rats as compared to the control
group. Although the precise mechanism of BBD neuro-
protection is not clear, the present in vitro and in vivo
results suggest that its protection might be involved
with the inhibition of release of ROS and inflammation
during cerebral ischemia.Conclusion
In conclusion, the present study shows that BBD with a
high membrane permeability protected the brain after
the focal cerebral ischemia. It also reduced lipid peroxi-
dation and preserved superoxide dismutase activity from
the ischemic brain. The protective mechanisms of BBD
might be involved with the inhibition of JNK MAPK,
COX-2, and caspase-3 signal pathway. These results ex-
tend our knowledge of BBD to its therapeutic potential.Abbreviations
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